Key positives include strong and improving liquidity, very low debt, and a growing asset base funded largely through equity rather than risky leverage. On the operating side, revenue is rising steadily, gross margins have improved, and cash burn is trending lower. Strategically, the company has differentiated manufacturing technology, a dual commercial and pharmaceutical model, and a meaningful patent portfolio around rare cannabinoids and novel small molecules.

Major risks center on continued losses, deeply negative retained earnings, and dependence on external financing to sustain operations. The company’s revenue base is still small relative to its cost structure, and profitability is not yet in sight. Clinical development risk is high, particularly in crowded and challenging therapeutic areas, and regulatory or legislative changes—such as potential restrictions on cannabinoid ingredients—could impair the BayMedica business. Dilution risk is also meaningful, as capital raises have been frequent, as suggested by repeated reverse splits.

The overall direction appears to be gradually improving: losses and cash burn are shrinking, liquidity is strong, and revenue from rare cannabinoids is gaining traction. At the same time, the investment case remains heavily dependent on uncertain milestones: advancing key drug candidates, securing partnerships, and navigating evolving regulation. If InMed can convert its technological and IP advantages into successful products while maintaining financial discipline, its position could strengthen considerably, but the path forward is inherently high‑risk and will likely remain volatile.